People | Products | Projection
LONDON 17 May 2022
Leonardo Royal Hotel London Tower Bridge
Bio Integrates 2022 Agenda
LONDON, 17 MAY 2022
Leonardo Royal Hotel London Tower Bridge
KEYNOTES, FIRESIDE CHATS AND PANEL DISCUSSIONS
PLEASE NOTE The agenda and timings have not been finalised so maybe subject to change.
DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.
Registration & Networking
08:00 – 08:50
Registration and networking
Welcome & Opening Remarks
08:50 – 09:00
Welcome & Opening Remarks
MARTINO PICARDO | Chairman | Discovery Park
Fireside Chat
09:00 – 09:20
Fireside Chat
An interview with: ANDREAS WALLNOEFER | Partner & Investor | Jeito Capital
Interviewed by: MARTINO PICARDO | Chairman | Discovery Park
Fireside Chat
09:20 – 09:40
Fireside Chat
An Interview with: Dr RUTH McKERNAN CBE | Neuroscientist, businesswoman and innovation leader
Interviewed by: TREVOR JONES CBE | Chairman and Board Member | e-Therapeutics, Respiratory Innovation Wales and Ascension Healthcare
PEOPLE
How do we assemble and accelerate our teams for success?
PRODUCTS
How do we protect, progress and pivot our products for maximal value?
PROJECTION
What does the future hold for life science investment, intellect and infrastructure?
Session 1
09:45 – 10:35
Living on the edge
With tech and biotech converging, how can we innovate and collaborate across the sector edges? Does innovation have to come from within, or can it come from CDMOs?
Making your product fit for purpose
How are you responding to the increasing interest, pressure, regulation, and legislation around the ethics, provenance, and sustainability of products? Are you ready? Can you see market opportunities?
Go big or go home
The Government’s Industrial Strategy and commitment to life science funding relies on companies scaling their science in the UK. How do you scale up in a fragmented ecosystem?
Networking
10:40 – 11:10
Networking Coffee
Session 2
11:15 – 12:05
The C word
The culture within an organisation can be its success or downfall. How do we build management teams and leadership structures to create an inspiring company culture?
Protect at all costs
The costs of protecting your IP can ramp up rapidly. How can you plan your IP strategy efficiently and cost-effectively?
Value in, value out
With a greater focus on accelerating development timelines, investors are expecting quicker returns. How can we accelerate products to deliver maximum value for patients and investors?
Session 3
12:10- 13:00
Get out(sourced)!
Finding the right outsourcing partners to help develop and scale your products is critical to milestones and budgets. How can we ensure we are working with the right partners at the right time?
Transfer targets
Tech transfer departments in Universities are inundated with potential translational science. How do they select the projects to back?
Networking
13:00 – 14:10
Networking Lunch
Session 4
14:10 – 15:00
Been there, done that
Success stories from those who have felt the fire at their feet, bridged the valley of death, scaled and sold their companies.
Preparing for the Next Pandemic
COVID-19 taught the life science industry a great deal. Now it’s time to capitalise on that knowledge. How can academia, SMEs and the government accelerate new solutions, overcome clinical, manufacturing, regulatory and commercialisation hurdles, and make sure we’re fully armed to tackle the next potential threat?
Session 5
15:05 – 15:55
Girls just wanna have fun(ds)
Less than 5% of investment goes to female-led businesses. What are we doing to address the gender investment gap? How can we apply this across other under-represented groups?
Fuelling the genetic medicine revolution
Nucleic acid (mRNA and DNA) vaccines aren’t necessarily new, but recent outcomes during the COVID pandemic are stimulating a renaissance in the wider biopharmaceutical industry as drug manufacturers turn their attention to issues such as speed-to-market, faster scale-up and, of course, safety.
Where you lead
Selecting your lead investors and assembling your syndicate is pivotal to the success of a biotech. Do you pick your investors, or do they pick you?
Closing
15:55 – 16:05
Closing remarks
MARTINO PICARDO | Chairman | Discovery Park
Networking
16:05 – 16:55
Drinks Reception
Registration and networking
08:00 – 08:50
Fireside Chat
09:20 – 09:40
Dr Ruth McKernan CBE | Neuroscientist, businesswoman and innovation leader
PEOPLE
How do we assemble and accelerate our teams for succes?
Session 1:
Living on the edge
09:45 – 10:35
With tech and biotech converging, how can we innovate and collaborate across the sector edges?
Networking
Coffee
10:40 – 11:10
Session 2:
The C word
11:15 – 12:05
The culture within an organisation can be its success or downfall. How do we build management teams and leadership structures to create an inspiring company culture?
Networking
Lunch
13:00 – 14:10
Session 5
Girls just wanna have fun(ds)
15:05 – 15:55
Less than 5% of investment goes to female-led businesses. What are we doing to address the gender investment gap? How can we apply this across other under-represented groups?
Networking
Drinks Reception
16:05 – 16:55
PRODUCTS
How do we protect, progress and pivot our products for maximal value?
Session 1:
Making your product fit for purpose
09:45 – 10:35
How are you responding to the increasing interest, pressure, regulation, and legislation around the ethics, provenance, and sustainability of products? Are you ready? Can you see market opportunities?
Networking
Coffee
10:40 – 11:10
Session 2:
Protect at all costs
11:15 – 12:05
The costs of protecting your IP can ramp up rapidly. How can you plan your IP strategy efficiently and cost-effectively?
Session 3:
Get out(sourced)!
12:10- 13:00
Finding the right outsourcing partners to help develop and scale your products is critical to milestones and budgets. How can we ensure we are working with the right partners at the right time?
Networking
Lunch
13:00 – 14:10
Session 4:
Been there, done that
14:10 – 15:00
Success stories from those who have felt the fire at their feet, bridged the valley of death, scaled and sold their companies.
Session 5:
Fuelling the genetic medicine revolution
15:05 – 15:55
Nucleic acid (mRNA and DNA) vaccines aren’t necessarily new, but they’re driving a renaissance in the biopharmaceutical industry as drug manufacturers turn their attention to issues such as speed-to-market, faster scale-up and, of course, safety.
Networking
Drinks Reception
16:05 – 16:55
PROJECTION
What does the future hold for life science investment, intellect and infrastructure?
Session 1:
Value in, value out
09:45 – 10:35
With a greater focus on accelerating development timelines, investors are expecting quicker returns. How can we accelerate products to deliver maximum value for patients and investors?
Networking
Coffee
10:40 – 11:10
Session 2:
Go big or go home
11:15 – 12:05
The Government’s Industrial Strategy and commitment to life science funding relies on companies scaling their science in the UK. How do you scale for success?
Session 3:
Transfer targets
12:10- 13:00
Tech transfer departments in Universities are inundated with potential translational science. How do they select the projects to back?
Networking
Lunch
13:00 – 14:10
Session 4:
Preparing for the Next Pandemic
14:10 – 15:00
COVID-19 taught the life science industry a great deal. Now it’s time to capitalise on that knowledge. How can academia, SMEs and the government accelerate new solutions, overcome clinical, manufacturing, regulatory and commercialisation hurdles, and make sure we’re fully armed to tackle the next potential threat?
Session 5
Where you lead
15:05 – 15:55
Selecting your lead investors and assembling your syndicate is pivotal to the success of a biotech. Do you pick your investors, or do they pick you?
Networking
Drinks Reception
16:05 – 16:55
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.
People | Products | Projection